Ad
related to: new treatment for lgl leukemia
Search results
Results from the WOW.Com Content Network
Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an unexplained, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood. [1] It is divided in two main categories: T-cell LGL leukemia (T-LGLL) and natural-killer (NK)-cell LGL leukemia (NK-LGLL).
Aggressive NK-cell leukemia is a disease with an aggressive, systemic proliferation of natural killer cells (NK cells) and a rapidly declining clinical course. [ 1 ] [ 2 ] [ 3 ] It is also called aggressive NK-cell lymphoma .
The center's director, Thomas P. Loughran Jr., discovered and is considered a leading expert in large granular lymphocytic (LGL) leukemia. He succeeded Michael J. Weber, who stepped down in 2013 after twelve years of service. [10] UVA Cancer Center is funded as a partner in the federal Cancer Moonshot. [11]
In organized studies of new treatments for cancer, the pre-clinical development of drugs, devices, and techniques begins in laboratories, either with isolated cells or in small animals, most commonly rats or mice. In other cases, the proposed treatment for cancer is already in use for some other medical condition, in which case more is known ...
“Lucas and I practically lived in the hospital,” says his mother, Jessica Encalada. “We couldn’t see our family for months.”
The most common T-cell leukemia is precursor T-cell lymphoblastic leukemia. [1] It causes 15% of acute leukemias in childhood, and also 40% of lymphomas in childhood. [1] It is most common in adolescent males. [1] Its morphology is identical to that of precursor B-cell lymphoblastic leukemia. [1] Cell markers include TdT, CD2, CD7. [1]
Natural killer cells, also known as NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system.They are a kind of large granular lymphocytes [1] [2] (LGL), and belong to the rapidly expanding family of known innate lymphoid cells (ILC) and represent 5–20% of all circulating lymphocytes in humans. [3]
Thomas P. Loughran, Jr. is an American physician-scientist who specializes in cancer research and treatment. He became director of the University of Virginia Cancer Center, F. Palmer Weber-Smithfield Foods Professor of Oncology Research and Professor of Medicine at the University of Virginia on August 15, 2013. [1]
Ad
related to: new treatment for lgl leukemia